Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 6/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010259 | 0.89 | MME (0.46) | FOLH1NAALAD2MMEL3MBTL1 | |
| SCHEMBL475962 | 0.80 | FOLH1 (0.54) | FOLH1NAALAD2MMEMEN1KMT2A | |
| SCHEMBL475961 | 0.80 | FOLH1 (0.54) | FOLH1NAALAD2MMEMEN1KMT2A | |
| SCHEMBL6010134 | 0.78 | FOLH1 (0.49) | FOLH1NAALAD2MMEMEN1KMT2A | |
| SCHEMBL6010145 | 0.78 | FOLH1 (0.49) | FOLH1NAALAD2MMEMEN1KMT2A | |
| SCHEMBL29664067 | 0.78 | MME (0.56) | FOLH1NAALAD2MMEACE | |
| SCHEMBL28216930 | 0.78 | MME (0.56) | FOLH1NAALAD2MMEACE | |
| SCHEMBL27775469 | 0.77 | FOLH1 (0.48) | FOLH1NAALAD2MMEMEN1KMT2A | |
| SCHEMBL27775468 | 0.77 | FOLH1 (0.48) | FOLH1NAALAD2MMEMEN1KMT2A | |
| SCHEMBL6009834 | 0.77 | TGFBR1 (0.40) | MMEMEN1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | FOLH1 1267/4885NAALAD2 114/4885MME 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.